Talaporfin

Generic Name: Talaporfin

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₄₁N_₅O_₉

CAS Number: 110230-98-3

Unique Ingredient Identifier: P4ROX5ELT2

Background: Talaporfin has been investigated for the treatment of Port-Wine Stain and Benign Prostatic Hyperplasia.

Clinical Trials

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Saline
Drug: talaporfin sodium
Device: Drug Activator 200 J/cm
Device: Drug Activator 100 J/cm

First Posted Date: 2014-12-29

Last Posted Date: 2018-08-08

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 225

Registration Number: NCT02326454

Novel Treatment for Port Wine Stain Birthmarks

Phase 1

Completed

Conditions: Port-Wine Stain

Interventions: Drug: Talaporfin sodium

First Posted Date: 2013-08-16

Last Posted Date: 2022-11-01

Lead Sponsor: University of California, Irvine

Target Recruit Count: 7

Registration Number: NCT01924273

Locations: 🇺🇸
Beckman Laser Institute, Irvine, California, United States

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: talaporfin sodium
Device: Transurethral illumination with light emitting diodes
Procedure: Placement

First Posted Date: 2009-06-11

Last Posted Date: 2012-11-16

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 21

Registration Number: NCT00918034

Locations: 🇦🇺
Princess Alexandra Hospital, Wolloongabba, Australia
🇳🇿
Canterbury Urology Research Trust Hiatt Chambers St. George's Medical Centre, Christchurch, New Zealand
🇦🇺
Royal Brisbane and Women's Hospital Center of Clinical Research, Herston, Australia

and more 5 locations

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Phase 1

Completed

Conditions: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: Talaporfin sodium
Procedure: Placement of device in prostate urethra
Device: Transurethral illumination with light emitting diodes (Litx™ BPH Device)

First Posted Date: 2008-07-03

Last Posted Date: 2012-11-16

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 12

Registration Number: NCT00709488

Locations: 🇺🇸
Urology San Antonio Research, San Antonio, Texas, United States
🇺🇸
Seattle Urological Associates, Seattle, Washington, United States
🇺🇸
Integrity Medical Research, Mountlake Terrace, Washington, United States

and more 3 locations

Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases

Phase 3

Completed

Conditions: Liver Metastases
Neoplasm Metastasis
Colorectal Neoplasms
Neoplasm Recurrence, Local

Interventions: Drug: Talaporfin sodium
Drug: FOLFOX4 regimen
Procedure: Percutaneous placement of device in liver metastases
Device: Interstitial light emitting diodes
Drug: FOLFIRI regimen

First Posted Date: 2007-02-27

Last Posted Date: 2015-08-25

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 483

Registration Number: NCT00440310

Locations: 🇧🇦
Clinical Centre of the University of Sarajevo, Institute of Oncology, Sarajevo, Bosnia and Herzegovina
🇭🇷
Clinical Centre Zagreb, Clinical Oncology, Zagreb, Croatia
🇩🇪
Katholisches Krankenhaus St. Johann Nepomuk, Erfurt, Germany

and more 54 locations

A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

Phase 3

Completed

Conditions: Liver Neoplasms
Carcinoma, Hepatocellular

Interventions: Drug: Talaporfin sodium
Procedure: Standard Care
Device: Interstitial Light Emitting Diodes
Procedure: Percutaneous placement of device in the liver

First Posted Date: 2006-07-21

Last Posted Date: 2015-01-30

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 208

Registration Number: NCT00355355

Locations: 🇮🇳
Cancer Clinic, Nagpur, India
🇲🇾
Island Hospital, Penang, Malaysia
🇵🇱
Centralny Szpital Kliniczny MSWiA, Warsaw, Poland

and more 31 locations

Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular
Liver Neoplasms

First Posted Date: 2005-07-22

Last Posted Date: 2007-12-07

Lead Sponsor: Light Sciences Oncology

Target Recruit Count: 25

Registration Number: NCT00122876

Locations: 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan
🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
🇸🇬
Singapore General Hospital, Singapore, Singapore

and more 6 locations

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Phase 1

Terminated

Conditions: Macular Degeneration
Choroidal Neovascularization

First Posted Date: 2005-01-24

Last Posted Date: 2010-03-12

Lead Sponsor: Light Sciences LLC

Target Recruit Count: 27

Registration Number: NCT00102115

Locations: 🇺🇸
Texas Retina, Dallas, Texas, United States

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

Phase 2

Completed

Conditions: Liver Metastasis
Colorectal Neoplasms
Liver Neoplasms
Neoplasm Metastasis

First Posted Date: 2004-06-03

Last Posted Date: 2007-04-11

Lead Sponsor: Light Sciences LLC

Target Recruit Count: 25

Registration Number: NCT00083785

Locations: 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases

Phase 2

Completed

Conditions: Liver Metastasis
Colorectal Neoplasms
Liver Neoplasms
Neoplasm Metastasis

First Posted Date: 2003-09-08

Last Posted Date: 2006-09-19

Lead Sponsor: Light Sciences LLC

Target Recruit Count: 25

Registration Number: NCT00068068

Locations: 🇺🇸
HealthOne Alliance/Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Eastern Carolina University, School of Medicine, Greenville, North Carolina, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy